Rare Kidney Tumors

1. Front Matter

   Pages i-ix

   PDF

2. Hereditary Renal Cell Carcinomas

   • Eric Jonasch, Patrick G. Pilie

   Pages 1-10

3. Wilms Tumor-Nephroblastoma

   • Marie V. Nelson, Arnauld Verschuur, Jeffrey S. Dome

   Pages 11-29

4. Renal Cell Carcinoma in Children

   • Ryan D. Bitar, Najat C. Daw

   Pages 31-41

5. Chromophobe Renal Cell Carcinoma

   • Aaron R. Lim, W. Kimryn Rathmell

   Pages 43-51

6. Papillary Renal Cell Carcinoma

   • Ramaprasad Srinivasan, Kai Hammerich

   Pages 53-63

7. Renal Medullary Carcinoma

   • Pavlos Msaouel, Priya Rao, Nizar M. Tannir

   Pages 65-75

8. Collecting Duct Carcinoma

   • Hendrik Van Poppel, Evelyne Lerut, Raymond Oyen, Maria Debiec-Rychter, Herlinde Dumez, Maarten Albersen et al.

   Pages 77-92

9. TFE/Translocation Morphology Renal Cell Carcinoma

   • James I. Geller, Nicholas G. Cost, Mariana M. Cajaiba

   Pages 93-104

10. Renal Cell Carcinoma with Sarcomatoid Features

    • Borchiellini Delphine, Ambrosetti Damien, Barthélémy Philippe

    Pages 105-128

This book provides clinicians with clear guidance on treatment decision-making in patients with rare kidney cancers. After a brief review on epidemiology, pathology, and biology, each chapter focuses on the multidisciplinary management of a particular tumor subtype using the full range of available cancer therapy modalities, including surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy. Emerging therapies and future directions in the management of each cancer subtype are also discussed. The chapters are all written by multidisciplinary teams of international experts comprising at least a urologist, a medical oncologist, and a pathologist.

Rare kidney cancers represent 15% of renal cell carcinomas. In comparison with clear cell renal cell carcinomas, little is known about the biology of such cancers, and few trials have reported on the efficacy of targeted therapies in the metastatic setting. Optimal management thus poses significant challenges and often requires a multidisciplinary team. This book will be an ideal reference guide for all clinicians involved in the care of patients with these orphan tumors.

• Rare Kidney Cancer
• Management
• Surgery
• Chemortherapy
• Orphan Renal Cell Carcinoma
• Targeted Therapy

• Department of Hematology and Oncology, Strasbourg University Hospital, Hopital Civil, Strasbourg, France

  Gabriel G. Malouf

• Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, USA

  Nizar M. Tannir

Dr. Gabriel G. Malouf, is professor of medical oncology in Strasbourg University and researcher at the Institute of Genetics and Molecular and Cellular Biology (IGBMC). A staff member of the department of medical oncology, Dr Malouf’s clinical and translational research focus on genitourinary malignancies.

Doctor Malouf earned a medical degree at the University of Paris Descartes (2012). After completing a residency program in medical oncology, Dr Malouf was postdoctoral postdoctoral follow at MD Anderson cancer center. After returning to Paris, Dr Malouf earned a PhD in cancer epigenetics (2014). Dr Malouf developed an expertise in rare kidney cancers, especially translocation renal cell carcinoma, medullary renal cell carcinomas and collecting duct carcinomas. Dr Malouf published more than 50 original papers in high-impact journals such as Clinical Cancer Research, Cancer Research and Genome Biology. In addition, Dr Malouf serve as faculty member for main meetings such as ASCO Genitourinary and EMUC (European Multidisciplinary Meeting on Urological Cancers) meetings. Dr Malouf is the coordinator of the research programs at the medical oncology department. His current focus is to develop a translational research program focusing on deciphering genetic and epigenetic aberrations of rare genitourinary malignancies. 

Dr. Nizar M. Tannir, is Professor and Deputy Chair of the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center, and is a clinical investigator with expertise in trial design. Dr. Tannir has conducted numerous clinical trials in renal cell carcinoma (RCC), and is an expert on rare kidney cancers, particularly, translocation RCC (Xp11.2) and renal medullary carcinoma (RMC). He co-chairs a think-tank on RMC, bringing together world experts from different fields to accelerate discovery and novel therapeutics for this devastating orphan cancer. Dr. Tannir has authored more than 150 original manuscripts and several book chapters. He is editor of Renal Cell Carcinoma, a book published by Oxford University Press in 2014. Dr. Tannir co-chairs a yearly urological oncology symposium at MDACC, and serves on the scientific and medical advisory board of the Kidney Cancer Association. Dr. Tannir’s research is focused on deciphering the molecular underpinnings of RMC and Xp11.2. He is Principal Investigator of several clinical trials in advanced clear-cell and non-clear cell RCC, including rare variants, with emphasis on identification of prognostic and predictive biomarkers. Dr. Tannir was voted Teacher of The Year four times, and received numerous awards including the Gerald P. Bodey Award for Excellence in Education, the Waun Ki Hong Award for Leadership in Education, and the Melvin L. Samuels Award for Excellence in Patient Care.

Policies and ethics